Skip to content
DataLookout
Menu

NCT03829254

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

StatusRecruiting
PhasePhase 1/2
SponsorNuCana plc
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Aug 2026 to Jul 2027
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: details revised at 12 of 21 entries
  2. Notable Eligibility criteria shortened, about 61 words
    • Site details revised at 4 of 9 sites
    v13
  3. Notable Eligibility criteria expanded, about 60 words
    • Study sites: 5 to 9
    v12
  4. Notable Primary and study completion dates: Jun 2024 to Aug 2026
    • Eligibility criteria expanded, about 54 words
    • Enrollment target: 94 to 135
    v11
  5. Minor Primary and study completion dates: Jan 2024 to Jun 2024v10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Primary and study completion dates: Sep 2023 to Jan 2024v9
  2. Notable Eligibility criteria expanded, about 114 words
    • Secondary endpoints: 10 to 21
    v8
  3. Minor Study sites: 3 to 5v7
  4. Notable Primary and study completion dates: Jul 2022 to Sep 2023v6 Show 4 more changesShow less
    • Eligibility criteria expanded, about 250 words
    • Interventions: NUC-7738 (Drug) to NUC-7738 (Drug), Pembrolizumab (Drug)
    • Secondary endpoints: details revised at 4 of 10 entries
    • Study arms: 1 to 2
  5. Notable Phase: Phase 1 to Phase 1/2v5 Show 5 more changesShow less
    • Eligibility criteria expanded, about 47 words
    • Primary endpoints: 5 to 11
    • Secondary endpoints: 7 to 10
    • Site contacts updated at 2 of 3 sites
    • Study title expanded, about 4 words
  6. Notable Enrollment target: 61 to 94
    • Primary and study completion dates: Nov 2021 to Jul 2022
    • Eligibility criteria shortened, about 8 words
    v4
  7. Notable Primary and study completion dates pushed to Nov 2021
    • Eligibility criteria expanded, about 7 words
    • Study description shortened, about 416 words
    • Site contacts updated at 3 of 3 sites
    v3
  8. Notable Start date changed from estimate of Feb 2019 to Jun 17, 2019v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of patients with dose-limiting toxicities
Timeframe: From the date of consent until 30 days after the last dose of NUC-7738 administered
Number of patients with treatment-emergent adverse events (CTCAE v5.0)
Timeframe: From the date of consent until 30 days after the last dose of NUC-7738 administered
Number of patients with clinically significant laboratory changes (CTCAE v5.0)
Timeframe: From the date of consent until 30 days after the last dose of NUC-7738 administered
Number of patients with changes in physical exam, vital signs, and serial electrocardiograms.
Timeframe: From the date of consent until 30 days after the last dose of NUC-7738 administered
MTD for NUC-7738 administered via weekly and fortnightly dosing schedules in patients with advanced solid tumours
Timeframe: Until completion of Phase I (an average of 1 year)
Percentage change from baseline in tumour size
Timeframe: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
Objective response rate (ORR)
Timeframe: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
Duration of response (DoR)
Timeframe: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
Disease control rate (DCR)
Timeframe: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
Duration of stable disease (DoSD)
Timeframe: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
Progression free survival (PFS)
Timeframe: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Secondary (21)

Phase I: Plasma concentration of NUC-7738 at end of infusion (Cinf)
Phase I: Maximum observed plasma concentration (Cmax) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase I: Area under the plasma concentration-time curve (AUC) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase I: Elimination half-life (t½) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase I: Volume of distribution of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Show 16 moreShow less
Phase I: Clearance of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase II: Plasma concentration of NUC-7738 at end of infusion (Cinf)
Phase II: Maximum observed plasma concentration (Cmax) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase II: Area under the plasma concentration-time curve (AUC) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase II: Elimination half-life (t½) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase II: Volume of distribution of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Phase II: Clearance of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Percentage change from baseline in tumour size
ORR
DoR
DCR
DoSD
PFS
Number of patients with treatment-emergent adverse events (CTCAE v5.0)
Number of patients with clinically significant laboratory changes (CTCAE v5.0)
Number of patients with changes in physical exam, vital signs, and serial electrocardiograms.

Arms and interventions

NUC-7738Experimental

NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.

NUC-7738 + pembrolizumabExperimental

NUC-7738 administered by intravenous infusion on a weekly schedule on Days 1, 8 and 15 of a 21-day cycle. Pembrolizumab administered by intravenous infusion every 3 weeks on Day 1 of a 21-day cycle.

Drugs: NUC-7738, Pembrolizumab

Sites

9 sites in 1 country